secwatch.observer — SEC 8-K summary
======================================

Issuer:     Syndax Pharmaceuticals Inc (SNDX)
CIK:        0001395937
Form:       8-K
Filed at:   2023-12-20T23:59:59+00:00
Accession:  0000950170-23-071749
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Syndax closes $230M public offering of common stock at $18.50/share
-------------------------------------------------------------------

- Offering of 12,432,431 shares includes full exercise of underwriters' option to purchase 1,621,621 additional shares.
- Gross proceeds of approximately $230M; net proceeds after underwriting discounts and expenses expected.
- Post-offering shares outstanding as of Dec 19, 2023: 84,809,736.
- Goldman Sachs, J.P. Morgan, TD Cowen, and Stifel acted as joint book-running managers.
- Offering made under an existing effective shelf registration statement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1395937/000095017023071749/0000950170-23-071749-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1395937/000095017023071749/sndx-20231219.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-071749

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer